Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Holding GERN?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.03Last Year’s EPS
-$0.09Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -18.27%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong start for RYTELO's market presence, successful financial strategies, and promising growth potential both in the U.S. and internationally. However, high operating expenses and the dependency on market success pose challenges.Company Guidance
During the Geron Q3 2024 earnings call, the company provided guidance on several key metrics following the FDA approval and commercial launch of RYTELO. They reported $28.2 million in net product revenue for RYTELO in its first full quarter in the U.S., surpassing expectations and indicating robust market demand. The company emphasized the continued demand and momentum for RYTELO, supported by strong intellectual property, including orphan drug exclusivity extending to June 2031 and patent protection through August 2037. Geron highlighted its strategic financial moves, including a $125 million synthetic royalty transaction with Royalty Pharma and a $250 million debt financing deal, which together generated $250 million in gross proceeds. These moves are expected to provide the company with financial flexibility and potentially see them through to profitability without further equity financing. Looking ahead, Geron anticipates steady growth across all patient segments and is preparing for the EU commercialization of RYTELO, with a potential launch in select markets expected in 2026, contingent on regulatory approval.Successful Launch of RYTELO
RYTELO achieved $28.2 million in net product revenue in its first full quarter of U.S. sales, exceeding expectations and coming from 388 ordering centers.
Strong Intellectual Property Position
Geron's IP position and FDA's orphan drug exclusivity are expected to provide exclusivity in the U.S. through August 2037.
Financial Transactions Secured
Completed a synthetic royalty transaction and a debt financing transaction, generating $250 million in gross proceeds to support future growth.
Positive Initial Real-World Data
Real-world experience with RYTELO is consistent with clinical trials, with physicians managing cytopenia effectively.
Potential for EU Expansion
CHMP review of RYTELO marketing authorization for lower-risk MDS in Europe could be completed in late 2024 or early 2025, with a potential launch in select EU markets by 2026.
---
GERN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GERN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $4.27 | $4.29 | +0.47% |
| Aug 08, 2024 | $4.56 | $4.60 | +0.88% |
| May 02, 2024 | $4.08 | $3.95 | -3.19% |
| Feb 28, 2024 | $2.06 | $1.95 | -5.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Geron Corp (GERN) report earnings?
Geron Corp (GERN) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Geron Corp (GERN) earnings time?
Geron Corp (GERN) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GERN EPS forecast?
GERN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.03.
---